Related Experiment Videos
Body temperature discriminates between full and partial benzodiazepine receptor agonists
1Department of Pharmacology, School of Medical Sciences, University, Walk, Bristol, U.K.
European Journal of Pharmacology
|August 28, 1990
Summary
Full agonists like loprazolam caused hypothermia in mice, while partial agonists did not. Body temperature changes can distinguish between full and partial agonists at benzodiazepine receptors.
Area of Science:
- Pharmacology
- Neuroscience
- Biomedical Science
Background:
- Benzodiazepines are a class of psychoactive drugs that bind to the benzodiazepine receptor.
- Agonists at this receptor can be classified as full or partial, depending on their efficacy.
- Understanding the differences between full and partial agonists is crucial for drug development and therapeutic applications.
Purpose of the Study:
- To investigate the effects of full and partial agonists of the benzodiazepine receptor on body temperature in mice.
- To determine if body temperature can serve as a reliable indicator for differentiating between full and partial benzodiazepine receptor agonists.
Main Methods:
- Administration of varying doses (1-30 mg/kg i.p.) of benzodiazepine and beta-carboline compounds to mice.
- Measurement of rectal body temperature in response to drug administration.
- Comparison of temperature changes induced by full agonists (loprazolam, ZK 93423) versus partial agonists (Ro 17-1812, ZK 91296).
Main Results:
- Full agonists, loprazolam and ZK 93423, induced dose-dependent hypothermia in mice, with maximal effects at low doses.
- Partial agonists, Ro 17-1812 and ZK 91296, did not significantly alter rectal temperature even at receptor-saturating doses (up to 30 mg/kg i.p.).
Conclusions:
- Body temperature regulation in mice is sensitive to the efficacy of benzodiazepine receptor agonists.
- Rectal temperature measurement is a viable and useful method for discriminating between full and partial agonists acting on the benzodiazepine receptor.
- These findings have implications for the pharmacological characterization of novel benzodiazepine receptor ligands.